News BRAIN Biotech AG

Equities

BNN

DE0005203947

Environmental Services & Equipment

Real-time Estimate Tradegate Other stock markets 10:25:43 2026-03-09 am EDT			5-day change	1st Jan Change
2.290 ^EUR	-2.14%		-8.20%	-11.11%

Feb. 24	BRAIN Biotech AG Reports Earnings Results for the First Quarter Ended December 31, 2025	CI
Jan. 20	BRAIN Biotech AG, 2025 Earnings Call, Jan 14, 2026

All News

03:45am	BRAIN Biotech : Sustainability Report VSME for FJ 2023/24	PU
Feb. 25	BRAIN Biotech : Management Statement 3M 2025/26 (BRAIN Managementstatement 3M 2025 26 )	PU
Feb. 25	BRAIN Biotech announces 3M 25/26 results and breakthrough at BioIncubator company SolasCure: Aurase® Wound Gel showing strong clinical evidence of superior debridement and healing in chronic wounds	PU
Feb. 25	BRAIN Biotech : Quarterly Statement as of 31 December 2025 (3M)	PU
Feb. 25	BRAIN Biotech announces 3M 25/26 results and breakthrough at BioIncubator company SolasCure: Aurase Wound Gel showing strong clinical evidence of superior debridement and healing in chronic wounds	EQ
Feb. 24	BRAIN Biotech AG Reports Earnings Results for the First Quarter Ended December 31, 2025	CI
Jan. 20	BRAIN Biotech AG, 2025 Earnings Call, Jan 14, 2026
Jan. 14	BRAIN Biotech : Management Statement 12M 2024/25 (BRAIN Managementstatement 12M 2024 25)	PU
Jan. 14	BRAIN Biotech : ESG Data Sheet 2023/24	PU
Jan. 14	FY 2024/25: BRAIN Biotech AG benefits from successful monetization of projects and strong corporate cost control	EQ
Jan. 14	BRAIN Biotech AG Provides Revenue Guidance for the Year 2025/2026	CI
Jan. 13	BRAIN Biotech AG Reports Earnings Results for the Full Year Ended September 30, 2025	CI
25-09-09	BRAIN Biotech : Johan Jansén-Storbacka takes over as head of BRAINBiocatalysts' enzyme product business	PU
25-09-03	BRAIN Biotech AG Announces Executive Changes	CI
25-09-03	BRAIN Biotech AG appoints Johan Jansén-Storbacka as Executive Vice President of the BRAINBiocatalysts´ enzyme products business	EQ
25-08-28	BRAIN Biotech AG Reports Earnings Results for the Third Quarter and Nine Months Ended June 30, 2025	CI
25-08-28	BRAIN Biotech : Management Statement 9M 2024/25 (BRAIN Management Statement 9M24 25)	PU
25-08-28	BRAIN Biotech reports dynamic Q3 revenue growth in core segment BRAINBiocatalysts	EQ
25-08-28	BRAIN Biotech : Quarterly Statement as of 30 June 2025 (9M)	PU
25-08-28	BRAIN Biotech AG Updates Sales Guidance for the Year 2025	CI
25-08-25	Corbion, BRAIN Biotech to Jointly Develop Biobased Antimicrobial Compounds	MT
25-08-25	Corbion and BRAIN Biotech team to shape the future of innovation in nature-based ingredient technologies	EQ
25-08-25	Corbion and Brain Biotech Ag Team to Shape the Future of Innovation in Nature-Based Ingredient Technologies	CI
25-07-23	Brain Biotech Ag Appoints Ursula La Cognata as Member of Supervisory Board, Effective July 11, 2025	CI
25-07-23	Experienced biotechnology expert joins the Supervisory Board of BRAIN Biotech AG	EQ